Unlicensed and off label drug use in paediatric wards: prospective studyBMJ 1998; 316 doi: https://doi.org/10.1136/bmj.316.7128.343 (Published 31 January 1998) Cite this as: BMJ 1998;316:343
- Sean Turner, clinical research pharmacista,
- Alexandra Longworth, research assistantb,
- Anthony J Nunn, director of pharmacya,
- Imti Choonara (), senior lecturer in paediatric clinical pharmacologyb
- a Department of Pharmacy, Alder Hey Children's Hospital, Liverpool L12 2AP
- b Institute of Child Health, Alder Hey Children's Hospital
- Correspondence to: Professor Imti Choonara Academic Division of Child Health, Derbyshire Children's Hospital, Derby DE22 3NE
- Accepted 23 September 1997
Objective: To determine the extent of use in children in hospital of drugs that are not specifically licensed for use in children (unlicensed) and of drugs that are used outside the terms of their product licence that apply to indication, age, dose, or route of administration (off label).
Design: Prospective study of drugs administered on paediatric medical and surgical wards for 13 weeks.
Setting: Regional children's hospital.
Subjects: Paediatric inpatients in medical and surgical wards.
Main outcome measures: Comparison of the use of each drug with its product licence to determine whether the drug was used in an unlicensed or off label manner.
Results: 2013 courses of drugs were administered to 609 paediatric patients in 707 admissions. 506 (25%) of the drug courses (prescriptions) were either unlicensed (139) or off label (367) uses. In 256 (36%) of the 707 admissions patients received one or more courses of an unlicensed or off label treatment in hospital.
Conclusions: Use of drugs in an off label or unlicensed manner to treat children is widespread. Drugs are more likely to be used in an off label manner than in an unlicensed manner.
Children in hospital are often treated with drugs not specifically licensed for use in children (unlicensed), and drugs are also used outside the terms of the product licence that apply to indication, age, dose, or route of administration (off label prescribing)
In this study 36% of children in 707 admissions received drugs prescribed in either an unlicensed or off label manner
Off label drug prescribing was more common than unlicensed drug prescribing
All drugs used to treat children should be subjected to the licensing process to ensure their quality, safety, and efficacy
The Medicines Control Agency, the pharmaceutical industry, and the NHS need to address the issue of drugs being used in these ways
Many drugs used to treat children in hospital are either not licensed for use in children (unlicensed) or are being prescribed outside the terms of the product licence (off label prescribing).1 2 There is considerable interest within the United Kingdom3 and the United States4 5 in unlicensed and off label drug use in children, but little information is available on the extent to which these types of treatments are used. We have reported our findings on unlicensed and off label drug use in a paediatric intensive care unit.6 We describe our findings on drug treatment in paediatric medical and surgical wards.
Patients and methods
A medical ward and a surgical ward at this children's hospital were each studied prospectively for 13 weeks between April and August 1996. Data were collected on all patients by the clinical research pharmacist (ST) and the research assistant (AL). The patient's age, date of birth, weight, diagnosis, and all drugs administered, the route of administration, dose, and indication for use were recorded. Use of the following was not recorded: standard intravenous replacement solutions, flushes of sodium chloride 0.9% or heparin used to maintain the patency of intravenous lines, blood products, oxygen therapy, and topical anaesthetic cream.
All drugs administered were assessed for unlicensed or off label use by ST using a classification system already described.3 Categories of unlicensed use included: modifications to licensed drugs (such as dispensing a drug in a different form, for example, crushing tablets to prepare a suspension), drugs that are licensed but the particular formulation is manufactured under a special licence (such as when an adult preparation is not suitable for use in children and a smaller dose must be formulated), new drugs available under a special manufacturing licence (such as caffeine injections for apnoea of prematurity), use of chemicals as drugs, drugs used before a licence has been granted, and imported drugs. The category of off label use included use of a drug in situations not covered by the product licence: administration of a greater dose or more often, administration for indications not described in the licence, administration to children outside the age range for which the product is licensed, the use of alternative routes of administration, and use when the product is contraindicated. The Association of the British Pharmaceutical Industry's Data Sheet Compendium 1995-96 was used as the primary reference source since product licences are not published but are summarised in the datasheet.7 If a drug was not included in the compendium, the package insert or the British National Formulary, March 1996 edition,8 was used as a secondary reference source. Most of the information published in the British National Formulary conforms to that in a drug's datasheet. If data could not be obtained from any of the reference sources, or if the information was ambiguous, the manufacturer was contacted.
A total of 609 patients in 707 admissions were included in the study. Of these, 384 (63%) of patients were male; this was due to the greater number of boys admitted for urogenital surgery. The ages of the patients ranged from 4 days to 20 years (median 2 years).
A total of 2013 drug courses (prescriptions) were administered to patients. Patients received between 0 and 21 different drugs. The median number of drugs administered was two on the surgical ward and one on the medical ward. The 10 most commonly administered drugs are shown in table 1.
In 506 (25%) of the 2013 prescriptions drugs were used in either an unlicensed (139) or off label manner (367). In 256 admissions patients received one or more drugs in an unlicensed or off label manner during their stay in hospital. Of the 1053 prescriptions written on the surgical ward 64 were for unlicensed uses and 201 were for off label uses. Of the 960 prescriptions written on the medical ward 75 were for unlicensed uses and 166 for off label uses. The drugs most frequently administered in an unlicensed or off label manner are shown in table 2 for the surgical ward and table 3 for the medical ward.
Many drugs were used both according to the terms of the licence and in an off label way. For example, morphine was administered to 80 children. Intravenous morphine is licensed for use in children aged 12 years and older. Thirty two children were eligible to be treated with morphine according to the terms of the product licence, but 48 children were treated with the drug in an off label manner. The number and type of off label or unlicensed uses are shown in tables 4 and 5 respectively. In 58 cases a drug was used in an off label manner for two reasons. Hence, in table 4) the total number of times a drug was used in an off label manner is greater than the total number of off label prescriptions.
The off label and unlicensed use of drugs to treat children is widespread and occurs in medical and surgical wards, as well as in critically ill children.6 Off label use occurs considerably more frequently than unlicensed use. Drugs are being used in children at ages for which they have not been licensed and, possibly, evaluated; at doses greater than that recommended by manufacturers; and for indications outside the terms of the product licence. It is not clear whether the use of drugs in these ways is appropriate.
The drugs most commonly used in an off label or unlicensed manner are usually established drugs for which there is a large amount of clinical information available—for example, morphine, paracetamol, salbutamol, ipratropium bromide. When a drug is already extensively used there is no commercial incentive for a pharmaceutical company to seek an amendment to the product licence. The Medicines Control Agency should therefore request an application for a product licence from companies whose products are being used in an off label or unlicensed manner and take into account published paediatric clinical trials and surveillance studies of off label use.
Newer drugs, such as diclofenac sodium and cisapride, are also being used in children. Clinical studies are needed to evaluate the efficacy and toxicity of these drugs in children. In the United States the Food and Drug Administration asks manufacturers to provide additional information on the use of established drugs in paediatric patients and to justify reasons for not performing paediatric studies when new drugs are submitted for licensing.4 9 10 The publication of the new European guidelines on the clinical investigation of medicinal products in children suggests that a similar approach will now be adopted in Europe.11
These new guidelines may result in a change of attitude among the pharmaceutical companies and the regulatory authorities. Clinical trials in children may be more difficult to organise than trials in adults, but they can be organised in children of all ages.12 13 14 Drugs used to treat children must be evaluated scientifically and the regulatory authorities must ensure that this is done. The National Institutes of Health in the United States has established paediatric pharmacology research units, which has resulted in an increase in the number of clinical trials in children (S Yaffe, personal communication, 1997). Each unit is led by an experienced paediatric clinical pharmacologist. The development of a similar approach in the United Kingdom should be encouraged. The establishment of a national centre to study drug treatment in children would increase the number of clinical trials in which children participate. Funding for such a centre should be a priority for the British pharmaceutical industry, the Medicines Control Agency, the NHS, and research charities.
Funding: North West Regional Health Authority.
Conflict of interest: None.
Contributors: IC initiated and designed the study, supervised the collection of data, analysed the data, and was involved in writing the paper. ST designed the data collection forms, coordinated and was involved in collecting and analysing the data, and was involved in writing the paper. AJN initiated and was involved in the design of the study, analysed the data, and was involved in writing the paper. AL helped design the data collection form, helped collect the data, and entered the data on to the computer.